MolMed

company

About

MolMed is a biotechnology company.

  • 101 - 250

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
€15M
Industries
Biotechnology
Founded date
Jan 1, 1996
Number Of Employee
101 - 250
Operating Status
Active

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes antitumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trials activities.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€15M
MolMed has raised a total of €15M in funding over 2 rounds. Their latest funding was raised on Dec 18, 2019 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 18, 2019 Debt Financing €15M 1 European Investment Bank Detail

Investors

Number of Lead Investors
Number of Investors
1
1
MolMed is funded by 1 investors. European Investment Bank are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Debt Financing